Semaglutide-based drugs, including Novo Nordisk's Ozempic and Wegovy, have seen explosive global demand in recent years for both diabetes management and weight loss, prompting regulators worldwide to fast-track generic alternatives.
Semaglutide-based drugs, including Novo Nordisk's Ozempic and Wegovy, have seen explosive global demand in recent years for both diabetes management and weight loss, prompting regulators worldwide to fast-track generic alternatives.
<iframe src="https://hindustansphere.com/embed/cluster/edc04ef1a74d07e3b137f4a5fc927bbdfafd7367" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Canada Approves First Generic Wegovy: What It Means For Weight-Loss Drug Prices"></iframe>
